Gamida Cell

bluebird

Pharma

Bluebird bio receives rival M&A bid worth 50% higher

Bluebird bio has received an unsolicited offer from Ayrmid, which proposes to acquire the gene therapy biotech at a 50% higher price upfront.

Angus Liu Mar 28, 2025 7:14pm

Lifeline

Struggling Gamida wins long-awaited FDA approval for Omisirge

Apr 17, 2023 4:46pm

US FDA

Gamida pushes back approval for blood cancer cell therapy

Nov 11, 2021 9:13am